Sanshui, Foshan, Guangdong Province, has created a new growth pole for biomedicine in the Greater Bay Area

Foshan, September 30 (Reporter Cheng Jingwei) Guangdong Provincial Drug Administration and Foshan Municipal People's Government recently signed the "Framework Agreement on Cooperation on Jointly Promoting the High-quality Development of Foshan's Biomedical Industry" (hereinafter referred to as the "Agreement"), proposing a series of specific measures and policy service guarantee measures
to support Foshan in the field of biomedical industry.

Among them, in the Yundonghai Biomedical Industrial Park (hereinafter referred to as "Yundonghai Industrial Park"), a biomedical industry public service platform was jointly established, and the Guangdong Provincial Drug Administration Review and Certification Center, the Guangdong Provincial Drug Inspection Institute, the Guangdong Medical Device Quality Supervision and Inspection Institute and other institutional platforms were extended to Foshan Sanshui
.
It is reported that Yundonghai Industrial Park is located in the core area of Sanshui District and is one of the top ten innovation-leading characteristic manufacturing parks in
Foshan.
With the blessing of this provincial policy, the development of Sanshui biomedical industry is expected to comprehensively improve the development level, build a first-class, world-class new industrial platform of 100,000 mu in the Bay Area, and become a new growth pole
for biomedicine in the Greater Bay Area.

According to reports, the Foshan Branch Center of the Evaluation and Certification Center of the Guangdong Provincial Drug Administration, the Drug Safety Evaluation Center of the Guangdong Provincial Drug Inspection Institute, the Foshan Inspection Office of the Guangdong Provincial Medical Device Quality Supervision and Inspection Institute and other institutional platforms will be extended to the Yundonghai Industrial Park
。 On the one hand, the relevant platform will support the construction of a biomedical scientific and technological achievements transformation base, biomedical science and technology cooperation and innovation zone, and promote the construction of a whole industry chain and life cycle management service platform of "innovation research and development-registration review-supervision and management-industrial service"; At the same time, it provides a green channel
for priority review and approval, administrative licensing, testing and inspection, and safety evaluation for enterprises settled in the Yundonghai Biomedical Industrial Park.

On the other hand, the relevant platform will carry out accurate services for enterprises, strengthen the guidance of the registration and declaration of innovative medical devices for enterprises, explore intervention from the research and development stage, and accelerate the product review and approval process
.

According to the agreement, the Guangdong Provincial Drug Administration and the Foshan Municipal People's Government will jointly promote the landing of the "Hong Kong and Macao Pharmaceutical and Electrical Equipment Connect" in Foshan, and promote the pilot production of Hong Kong and Macao drugs and medical devices in the Greater Bay Area to settle in the Yundonghai Industrial Park
.

Guangdong's "14th Five-Year Plan" clearly proposes to accelerate the development of the biomedical industry and form a competitive advantage
in the fields of biological medicine, chemical medicine, modern Chinese medicine, high-end medical equipment, and medical services.
As we all know, Foshan Sanshui has the unique location advantage of the Greater Bay Area and has a two-way advantage
for the domestic and international markets.
As the "axis" of Sanshui's biomedical industry map, Yundonghai Industrial Park has 10,000 mu of industrial development space, 10,000 mu of national wetland park, and 10,000 mu of natural ecological green core, and is the only biomedical industrial park
in the Guangdong-Hong Kong-Macao Greater Bay Area that can be developed with land of more than 10,000 mu.

At present, Yundonghai Industrial Park has introduced 2 projects of more than 10 billion yuan, 1 project of more than 5 billion yuan, more than 100 reserve projects, and the total intended investment of more than 80 billion yuan
.
With the settlement of the platform for the transformation of scientific and technological achievements, it will further promote the integration of clinical medicine into the whole process of biomedicine and medical device research and development, and Yundonghai Industrial Park is expected to become an important part
of the preemptive layout of future industries.

"Sanshui has obvious location advantages, superimposed on government support and other advantages, and is an excellent virgin land
for the development of the biomedical industry.
" Xie Jiasheng, CEO of Guangdong Medical Valley, believes that they chose to develop in Sanshui because they are optimistic about the development potential and development advantages
of Sanshui.
(End)